Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Theranos, Inc.
EIR
•Theranos, Inc.•September 16, 2015

Theranos, Inc. – FDA EIR, Sep 16, 2015

Record Details

An FDA "For Cause" Level II QSIT inspection of Theranos, Inc. was conducted from August 25 to September 16, 2015, at its Newark, CA facility. The inspection focused on the company's Class II In Vitro Diagnostic medical devices, specifically their Capillary Tube Nanotainers (CTNs). Throughout the inspection, Theranos repeatedly challenged the FDA's jurisdiction, asserting their product was under CLIA Lab control, not a Class II medical device requiring 510(k) clearance, despite prior FDA communication. The inspection identified several significant violations, leading to the issuance of a Form FDA-483. Key observations included the unapproved shipping of uncleared Class II medical devices in interstate commerce, inadequate complaint handling procedures where device failures were not properly investigated, and deficiencies in documenting Corrective and Preventive Actions (CAPA). Further issues involved the use of unvalidated software, failure to document supplier evaluations or establish acceptable supplier records, inadequate Device History Record procedures (e.g., not retaining product labels), and the absence of internal quality audits. Theranos' President and COO received the 483, indicating most observations would be corrected within seven days, with a formal written response promised within 15 working days, notwithstanding ongoing objections to the FDA's authority.

Company
Theranos, Inc.
Inspection date
September 16, 2015
Product type
devices
Office
San Francisco District Office
People
  • Stayce E. Beck
  • Mary R. Hole (Supervisory Investigator)
  • Yung W. Chan (Senior Advisor)
View Company Profile

ID · 008171a5-1de8-46d5-aa30-8abe6ed4ebd3

Violation Codes10
21 CFR 862.167521 CFR 807.20(a)21 CFR 820.198(a)21 CFR 820.198(c)21 CFR 820.100(b)21 CFR 820.70(i)21 CFR 820.50(a)(1)21 CFR 820.50(a)(3)21 CFR 820.18421 CFR 820.22

Full citation text and observation details available on the Dashboard.

Other documents for Theranos, Inc.
  • 483 - 2015-09-16September 16, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Theranos, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.